POLYMORPHISMS OF DRUG TRANSPORTERS AND CLINICAL RELEVANCE - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 636

TABLE 21.2. ( Continued )
HUGO Outcome

Name SNP Population Marker Effect Ref.

340 HIV + patients Virologic failure, efavirenz

PK

3435TT associated with
decreased likelihood of
virologic failure but not
efavirenz exposure

137

149 drug-naive HIV +
patients

CD4 cell recovery No statistical association 140

31 drug-naive HIV +
patients

Viral decay, CD4 cell
recovery, ritonavir PK

No statistical association 139

461 drug-naive HIV +
Caucasians

Time to virological success
or failure or
immunological failure

Trend toward earlier
virological failure in
3435CC group

141

32-43 HIV + patients LPV plasma trough levels,

12-hEFV levels

No statistical association 192

200 drug-resistant, 155
drug-responsive patients

Refractory epilepsy 3435CC associated with

drug-resistant epilepsy

147

230 drug-resistant, 170
drug-responsive patients

Refractory epilepsy No statistical association 151

401 drug-resistant; 208
drug-responsive patients

Refractory epilepsy No statistical association 150

63 drug-resistant; 108
drug-responsive Koreans

Refractory epilepsy No statistical association 131

↑

30 early-onset, 77
late-onset (59
pesticide-exposed)
patients

Onset of Parkinson's
disease

Frequency of 3435TT in

exposed vs. nonexposed
patients (fivefold

157

↑ disease

risk; CT associated with